Attached files
| file | filename |
|---|---|
| 8-K - INTELLICELL BIOSCIENCES, INC. FORM 8-K - Intellicell Biosciences, Inc. | form8k.htm |
Exhibit 99.2
| USE BLACK INK ONLY - DO NOT HIGHLIGHT | ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Correction
(Pursuant to NRS Chapters 78, 78A, 80, 81, 82, 84, 86, 87, 87A, 88, 88A, 89 and 92A)
|
1.
|
The name of the entity for which correction is being made:
|
Intellicell Biosciences, Inc.
|
2.
|
Description of the Original document for which correction is being made:
|
Series E Preferred Stock Certificate of Designation
|
3.
|
Fling date of the original document for which correction is being made:
|
January 17, 2014
|
4.
|
Description of the inaccuracy or defect:
|
The series E Preferred Stock was incorrectly named and should be Series F Preferred Stock
|
5.
|
Correction of the inaccuracy or defect:
|
See attached certificate of designation of Series F Preferred Stock
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
| This form must be accompanied by appropriate fees |
Nevada Secretary of State Correction
Revised: 3-26-09
|
1
.
INTELLICELL BIOSCIENCES, INC.
a Nevada corporation
CERTIFICATE OF DESIGNATIONS, RIGHTS AND PREFERENCES OF
SERIES F PREFERRED STOCK
Intellicell Biosciences, Inc., a corporation organized and existing under the laws of the State of Nevada (the "Corporation"), hereby certifies that the following resolution was adopted by the Board of Directors ofthe Corporation (the "Board") on January 15,2014 in accordance with the provisions of its Articles of Incorporation (as may be amended from time to time, the "Articles oflncorporation") and bylaws. The authorized series of the Corporation's previously authorized preferred stock shall have the following designations, rights, preferences, privileges, powers and restrictions thereof, as follows:
RESOLVED, that pursuant to the authority granted to and vested in the Board in accordance with the provisions of the Articles of Incorporation and bylaws of the Corporation, the Board hereby authorizes a series of the Corporation's previously authorized preferred stock (the "Preferred Stock"), and hereby states the designation and number of shares, and fixes the relative rights, preferences, privileges, powers and restrictions thereof, as follows:
I. NAME OF THE CORPORATION
Intellicell Biosciences, Inc.
II. DESIGNATION AND AMOUNT; DIVIDENDS
A. Designation. The designation of said series of preferred stock shall be Series F Preferred Stock, $0.01 par value per share (the "Series F Preferred").
B. Number of Shares. The number of shares of Series F Preferred authorized shall be fifty-one (51) shares. Each share of Series F Preferred shall have a stated value equal to $0.01 (as may be adjusted for any stock dividends, combinations or splits with respect to such shares, the "Series F Stated Value").
C. Dividends: Initially, there will be no dividends due or payable on the Series F Preferred. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation's Articles of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate of Designation, which the Board shall promptly file or cause to be filed.
III. LIQUIDATION RIGHTS
The holders of Series F Preferred Stock shall have no rights (whether in the form of distributions or otherwise) in respect of any liquidation, dissolution or winding up of the Corporation, either voluntary or involuntary, ana shall be subordinate to ali other classes of the Corporation's capital stock in respect thereto.
2
IV. RANK
All shares of the Series F Preferred shall rank (i) senior to the Corporation's common stock, par value
$.001 per share ("Common Stock"), and any other class or series of capital stock of the Corporation
hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Article V, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series F Preferred (the "Pari Passu Shares") and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series F Preferred (the "Senior Shares"), in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.
V. VOTING RIGHTS
Each one (1) share of the Series F Preferred shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding shares of Common Stock eligible to vote at the time of the respective vote (the "Numerator"), divided by (y) 0.49, minus (z) the Numerator. For purposes of illustration only, if the total issued and outstanding shares of Common Stock eligible to vote at the time of the respective vote is
5,000,000, the voting rights of one share of the Series F Preferred shall be equal to 102,036 (0.019607 x
5,000,000) I 0.49)-(0.019607 X 5,000,000) = 102,036).
With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series F Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Articles of Incorporation or bylaws.
VI. PROTECTION PROVISIONS
So long as any shares of Series F Preferred are outstanding, the Corporation shall not, without first obtaining the unanimous written consent of the holders of Series F Preferred, (i) alter or change the rights, preferences or privileges of the Series F Preferred so as to affect adversely the holders of Series F Preferred or (ii) create Pari Passu Shares or Senior Shares.
VII. MISCELLANEOUS
A. Status of Redeemed Stock: In case any shares of Series F Preferred shall be redeemed or otherwise reacquired, the shares so redeemed or reacquired shall resume the status of authorized but unissued shares of preferred stock, and shall no longer be designated as Series F Preferred.
B. Lost or Stolen Certificates: Upon receipt by the Corporation of(i) evidence of the loss, theft, destruction or mutilation of any Preferred Stock certificate(s) and (ii) (A) in the case of loss, theft or destruction, indemnity (with a bond or other security) reasonably satisfactory to the Corporation or (B) in the case of mutilation, the Preferred Stock certificate(s) (surrendered for cancellation), the Corporation shall execute and deliver new Preferred Stock certificate(s).
C. Waiver: Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the holders of Series F Preferred granted hereunder may be waived as to all shares of Series F Preferred (and the holders thereof) upon the unanimous written consent of the holders of the Series F Preferred.
D. Notices: Any notices required or permitted to be given under the terms hereof shall be sent by prepaid certified or registered mail (return receipt requested), or delivered personally, by nationally recognized overnight carrier or by confirmed facsimile transmission, and shall be effective five (5) days after being placed in the mail, if mailed, or upon receipt or refusal of receipt, if delivered personally, by nationally recognized overnight carrier or confirmed facsimile transmission, in each case addressed to a party as set forth below, or such other address and telephone and fax number as may be designated in writing hereafter in the same manner as set forth in this Section.
3
If to the Corporation:
Intellicell Biosciences, Inc.,
460 Park Avenue, 17th FL
New York, NY 10022
Attention: Dr. Steven Victor, Chief Executive Officer
Telephone: (646) 576-8700
If to the holder of Series F Preferred, to the address listed in the Corporation's books and records.
IN WITNESS WHEREOF, the undersigned has signed this certificate as of the 17th day of
| INTELLICELL BIOSCIENCES, INC. | |||
|
January, 2014.
|
By:
|
/s/ Dr. Steven Victor | |
| Name: Dr. Steven Victor | |||
| Title: ChiefExecutive Officer | |||
4